Key result
CYP2C19 poor metabolizer genotype linked to ~4-fold higher risk of coronary microvascular disorder in women.
Why the study?
The role of CYP2C19 poor metabolizer genotype and low-grade inflammation in coronary microvascular disorder and their sex-specific impact remain unclear.
Is the CYP2C19 poor metabolizer genotype and low-grade inflammation associated with coronary microvascular disorder, and does this differ by sex?
Case-Control (n=162)
Is the CYP2C19 poor metabolizer genotype and low-grade inflammation associated with coronary microvascular disorder, and does this differ by sex?
Odds Ratio: 4.1 (95% CI 1.15–14.1)
Absolute Event Rate: 40.9% vs 13.8%
p-value: p=0.038
The CYP2C19 poor metabolizer genotype and elevated hs-CRP levels are independent predictors of coronary microvascular disorder exclusively in women.
May link CYP2C19 PM status to CMVD via hs-CRP in women; leaves open whether genotyping refines risk stratification.
Categorization as a cytochrome P-450 (CYP) 2C19 poor metabolizer (PM) is reported to be an independent risk factor for cardiovascular disease. It is correlated with an increase in the circulating levels of high-sense C-reactive protein (hs-CRP) in women only, although its role in coronary microcirculation is unclear. We examined sex differences in the impact of the CYP2C19 genotype and low-grade inflammation on coronary microvascular disorder (CMVD). We examined CYP2C19 genotypes in patients with CMVD (n = 81) and in healthy subjects as control (n = 81). CMVD was defined as the absence of coronary artery stenosis and epicardial spasms, the presence of inverted lactic acid levels between the intracoronary and coronary sinuses, or an adenosine triphosphate-induced coronary flow reserve ratio < 2.5. CYP2C19 PMs have two loss-of-function (LOF) alleles (*2, *3). Extensive metabolizers have no LOF alleles, and intermediate metabolizers have one LOF allele. The ratio of CYP2C19 PM and hs-CRP levels in CMVD was significantly higher than that of controls, especially in women (40.9 vs. 13.8%, P = 0.013; 0.11 ± 0.06 vs. 0.07 ± 0.04 mg/dl, P = 0.001). Moreover, in each CYP2C19 genotype, hs-CRP levels in CMVD in CYP2C19 PMs were significantly higher than those of the controls, especially in women (0.15 ± 0.06 vs. 0.07 ± 0.03, P = 0.004). Multivariate analysis for CMVD indicated that the female sex, current smoking, and hypertension were predictive factors, and that high levels of hs-CRP and CYP2C19 PM were predictive factors in women only (odds ratio 3.5, 95% confidence interval 1.26-9.93, P = 0.033; odds ratio 4.1, 95% confidence interval 1.15-14.1, P = 0.038). CYP2C19 PM genotype may be a new candidate risk factor for CMVD via inflammation exclusively in the female population.
No takes yet. Share an insight, caveat, or question.
Akasaka et al. (2016) conducted a case-control in Coronary microvascular disorder (n=162). CYP2C19 poor metabolizer genotype vs. Healthy controls / non-poor metabolizers was evaluated on Coronary microvascular disorder (OR 4.1, 95% CI 1.15-14.1, p=0.038). The CYP2C19 poor metabolizer genotype was a significant independent predictor of coronary microvascular disorder exclusively in women (OR 4.1; 95% CI 1.15-14.1; P=0.038).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: